布美他尼治疗儿童孤独症谱系障碍的研究进展  

Research progress on Bumetanide treatment for autism spectrum disorder in children

作　　者：段彩灵 郭岚敏[1,2] 周新玉 Duan Cailing;Guo Lanmin;Zhou Xinyu(School of Rehabilitation Medicine,Jiamusi University,Jiamusi 154000,China;Department of Child Health Care,the Third Affiliated Hospital of Jiamusi University,Jiamusi 154000,China)

机构地区：[1]佳木斯大学康复医学院,佳木斯154000 [2]佳木斯大学附属第三医院儿童保健科,佳木斯154000

出　　处：《中华实用儿科临床杂志》2024年第8期625-628,共4页Chinese Journal of Applied Clinical Pediatrics

基　　金：黑龙江省省属高等学校基本科研业务费科研项目(2020-KYYWF-0298);儿童智能康复团队项目(DJXSTD202413)。

摘　　要：孤独症谱系障碍(ASD)是一组以社会交流交往障碍、兴趣狭窄与重复刻板行为为核心症状的神经发育障碍性疾病。近年来其发病率逐年上升,病程常伴随终身,现临床治疗主要采用行为干预疗法,偶有使用药物辅助治疗其伴随症状,如易怒、感觉异常、睡眠问题和胃肠道问题等,但仍缺乏特异性药物治疗其核心症状。布美他尼是美国食品药品监督管理局批准的利尿剂,已被提出作为一种治疗ASD核心症状的候选药物。现主要就布美他尼治疗儿童ASD核心症状的最新研究进展进行综述,为布美他尼的研究和应用提供理论依据。Autism spectrum disorder(ASD)comprises neurodevelopmental disorders characterized by core symptoms of social communication disorders,restricted interests,and repetitive behaviors.With increasing incidence year by year,ASD may persist throughout life.The current clinical treatment is mainly behavioral intervention,occasionally supplemented with medication to treat the accompanying symptoms,such as irritability,paresthesia,sleep disorders,and gastrointestinal diseases,but there is still a lack of specific drugs targeting the core symptoms of ASD.Bumetanide,an U.S.Food and Drug Administration-approved diuretic,has been proposed as a candidate to treat the core symptoms of ASD.This article mainly reviews the latest research progress on Bumetanide treatment of core symptoms in children with ASD,providing a theoretical basis for the research and application of Bumetanide.

关 键 词：儿童 孤独症谱系障碍 布美他尼 Γ-氨基丁酸 

分 类 号：R749.94[医药卫生—神经病学与精神病学]